Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Debt to Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Debt to Equity data on record, last reported at $4.34 in Q2 2025.

  • For Q2 2025, Debt to Equity rose 107.49% year-over-year to $4.34; the TTM value through May 2025 reached $4.34, up 107.49%, while the annual FY2025 figure was $4.34, 107.49% up from the prior year.
  • Debt to Equity reached $4.34 in Q2 2025 per LFCR's latest filing, up from $3.74 in the prior quarter.
  • Across five years, Debt to Equity topped out at $65.35 in Q4 2023 and bottomed at -$20.06 in Q2 2023.
  • Average Debt to Equity over 5 years is $3.2, with a median of $0.87 recorded in 2021.
  • The widest YoY moves for Debt to Equity: up 9585.37% in 2023, down 4503.4% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $1.06 in 2021, then crashed by 36.63% to $0.67 in 2022, then surged by 9585.37% to $65.35 in 2023, then plummeted by 99.08% to $0.6 in 2024, then soared by 623.4% to $4.34 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $4.34 in Q2 2025, $3.74 in Q1 2025, and $0.6 in Q4 2024.